Law360, New York (November 15, 2006, 12:00 AM ET) -- Cobalt Laboratories Inc. has become the third generics maker in the past five weeks to settle litigation with GlaxoSmithKline over the patent for the migraine treatment Imitrex.
Cobalt Laboratories Inc., an affiliate of Cobalt Pharmaceuticals, followed in the footsteps of Spectrum Pharmaceuticals Inc. and Dr. Reddy’s Laboratories by settling with Glaxo over sumatriptan succinate tablets, Cobalt said on Wednesday.
As part of the settlement, Cobalt may distribute generic Imitrex in the U.S. in the first quarter of 2009, the generics maker said.
The remaining terms of...
Generics Maker Settles Imitrex Suit With Glaxo
To view the full article, take a free trial now.
